Here is our annual report of our progress this past year and future plans. Heffter’s largest supported study was recently completed, “Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial.”...
August 30, 2022 Dear Dr. Greer, It is my pleasure to thank you for the Heffter Research Institute’s recent gift of $138,405 to support Dr. Yvan Beaussant’s PATH study for patients receiving hospice care. Thanks to your ongoing support, the first PATH study participant has successfully completed...
Johns Hopkins Medicine was awarded a grant from the National Institutes of Health (NIH) to explore the potential impacts of psilocybin on tobacco addiction. This is the first NIH grant awarded in over a half century to directly investigate the therapeutic effects of a classic...
First, there have been changes at Heffter since our last newsletter. Carey Turnbull has succeeded George Greer as President. George has retired as Medical Director and is now Board Chair. Dave Nichols is Vice-President, and all three make up the Heffter Executive Committee....
This recent publication shows that since the founding of the Heffter Research Institute in 1993, Heffter-affiliated researchers account for 63% (17 of 27) of top-cited articles on classic psychedelics....
Purpose:
This study will investigate neurobiological and psychological effects of psilocybin-assisted therapy in people with major depressive disorder. The primary hypothesis is that psilocybin administered in a therapeutic context will result in neuroplastic changes that parallel improvement in symptoms of depression.
Recently there has been increased interest in microdosing LSD, that is, using doses of LSD that are not psychoactive (typically 10 micrograms). A standard recommendation is microdosing every three days. The basic idea derives from earlier studies of psychoactive doses of LSD or other psychedelics such as mescaline, where suggestions were made that the doses helped improve creativity. For years, we at Heffter have been interested in and have helped develop the scientific evidence related to the value of psychedelics. Given the increased interest in microdosing, it is worth exploring what we know and don't know on the topic, particularly given that LSD is a Schedule 1 drug and that possession even of a microdose is illegal.
The 100th scientific publication with Heffter support has just been published, marking a milestone achievement for Heffter! The first one, in 1998, was about the safety of hallucinogens. Most of the earlier papers were about the effects of MDMA and psilocybin in normal subjects, to...
